NCT03333005View on ClinicalTrials.gov

Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

October 26, 2018

Study Completion Date

October 26, 2018

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

APX001 with Standard of Care anti-fungal agent

safety assessment

Trial Locations (3)

50931

University of Cologne, Center for Integrated Oncology (CIO), Cologne

55131

Johannes Gutenberg, University of Mainz, Mainz

81377

University of Munich, Grosshadern Campus, Munich

Sponsors
All Listed Sponsors
collaborator

The Clinical Trials Centre Cologne

OTHER

lead

Basilea Pharmaceutica

INDUSTRY